EAM
BHVN

Eventide Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Eventide Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,129,100
Closed -$165M – 154
2022
Q2 		$165M Sell
1,129,100
-505,900
-31% -$64.6M 3.52% 1
2022
Q1 		$194M Hold
1,635,000
– – 3.04% 1
2021
Q4 		$225M Buy
1,635,000
+310,000
+23% +$39.4M 2.88% 2
2021
Q3 		$184M Sell
1,325,000
-665,797
-33% -$83.1M 2.43% 6
2021
Q2 		$193M Sell
1,990,797
-24,203
-1% -$1.96M 2.6% 6
2021
Q1 		$138M Buy
2,015,000
+231,239
+13% +$18.7M 2.04% 6
2020
Q4 		$153M Hold
1,783,761
– – 2.34% 8
2020
Q3 		$116M Hold
1,783,761
– – 2.27% 8
2020
Q2 		$130M Hold
1,783,761
– – 2.83% 5
2020
Q1 		$60.7M Buy
1,783,761
+149,761
+9% +$6.85M 1.97% 11
2019
Q4 		$89M Hold
1,634,000
– – 2.51% 6
2019
Q3 		$68.2M Buy
1,634,000
+811,000
+99% +$34.3M 2.25% 9
2019
Q2 		$36M Buy
823,000
+330,000
+67% +$18.6M 1.1% 29
2019
Q1 		$25.4M Hold
493,000
– – 0.87% 39
2018
Q4 		$18.2M Buy
493,000
+199,000
+68% +$7.17M 0.81% 44
2018
Q3 		$11M Buy
294,000
+40,000
+16% +$1.47M 0.41% 71
2018
Q2 		$10M Sell
254,000
-92,000
-27% -$2.92M 0.42% 70
2018
Q1 		$8.91M Buy
346,000
+104,000
+43% +$3.11M 0.42% 68
2017
Q4 		$6.53M Buy
242,000
+188,760
+355% +$5.2M 0.34% 79
2017
Q3 		$1.99M Hold
53,240
– – 0.11% 104
2017
Q2 		$1.33M Buy
+53,240
New +$1.23M 0.08% 107

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Eventide Asset Management's BHVN Position: Q3 2022 in Review

Eventide Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 1,129,100 shares — an estimated $165M sold.

Eventide Asset Management first reported a position in BHVN in Q2 2017 and held it in 21 quarters. The position peaked at $225M in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Eventide Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Eventide Asset Management sold 1,129,100 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $165M.
  • Eventide Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 21 quarters.
  • Eventide Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $225M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Eventide Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.